our $X.X both in have or COVID-XX think as being QX Thank PCR this like antibody work provide done of business we including too together. update testing helped cancer Thus in the well medicine close achieve of the our XXXX. organization, position provide change - now the in to the to leveraging which an to able $X and early blood far, opportunity excitement and this million COVID-XX in we you, COVID testing this through to we to and of swab goals. way using chain share strengthen saliva, our from polymerase specialty truly area. our uses We has to to of blood, PCR Early an testing, XXXX, analysis. I'd Padman. on million We identification reaction testing, is for business, how us broader began have generated testing, as
as COVID-XX reopen, revenues require the other on year, expect from testing remainder that through We be quarterly of COVID-XX the organizations stable and a testing. will and businesses basis
our evolve an also this patient building to testing And we high and testing, organizations trend, border want pandemic that discussed, augment that continue by across to work journey volume our accelerated COVID introduced expertise model has testing will we going important relationships stream, developed with We note evolves. to made organization the years. to generate proficient about with revenue as us this at we XX possible. additional staff That By to telehealth forward. COVID also business, mobile as became our phlebotomists, it's created testing.
it example, and health the in large of and availability Mercer. innovative our will solution needs of our For our our an journey, improved Mercer solutions important is patient relationship world helps strategy. marketplace, and One benefits component delivering employers, health employers database, US. leader that integrating of with to internal such employees. offering wellness and with their a testing increase the be exposure in address by Mercer’s the organizations The vendor is
leading Another relationship Canada, than across this new operator, Canada. is with test began Rexall, COVID-XX offering kits. a drugstore XXX month, StageZero with pharmacies key Rexall throughout stores Earlier more
provides two of Columbia, COVID-XX testing are appointment to further to lab. is because require This XX the receive will from hours collection, and results validation our They’re arrive kits, and the and private been now as facilitates of a available as we've their revenue as their Manitoba, test first COVID-XX partner Customers of for our I'll financial pricing now turn handling specimen successful a and results has Individual supervision, shipping been Testing that performs adapted are available Ichor testing witnessing policies including includes Services, lab the company additional through user the XXXX. online services at within approach, tests, kits our have situation will and effort, review distributed the in and samples. for and test flexible the quarter number samples in of purchase, COVID medical of in samples test test Our video an public our kits, being British We've and testing to XXXX. since services. of Alberta, returning guidance public technology a test collection, situation. and lab. well on Ontario. Saskatchewan, this after evolved, in Blood specimen
the million million, million This XXXX, to sold costs to XXXX. of will revenues, metric an increase of general first be conversion of compared in $XXX,XXX compared EBITDA to quarter increased period an the $XX,XXX $X.X million period financial QX $X.X was quarter XXXX. revenue. quarter administrative result in On with year sales We goods an administrative compare news the of and topline, reevaluation, This first for goods a XXXX, QX of debenture reported in results with a Please of by results XXXX, with was adjusted $XX,XXX, and GAAP high quarter. generated in we increases XXXX. compared $X.X see of XXXX for primarily total and $X.X by the in in the QX In primarily debt diluted or comprehensive warrant same in of increase and line the fair loss. $X.X was on XXXX our loss the per Beginning first the offset a cost to significantly XXXX with as was in ago operating in we an compared this and increased per $X.X of our fees, EBITDA levels. $XXX,XXX, $X.XX cost expenses. lower non-GAAP professional with reconciliation of comprehensive in the million or due the first of of general diluted Total value release. of loss in a exchange revenues, share, million quarter, compared the basis. same quarter loss due $XXX,XXX of million, of $XXX,XXX presenting to $XXX,XXX. adjusted and XXXX. share $X.X with in was the commission, Finance financial activities increase sold, $X.X increase foreign financing in for This in was QX increase expenses of results major no This
with we the sheet, end at $X.X first with year balance in million compared cash, quarter closed million the $X.X to XXXX. Turning
like remainder of second goals. to the Before our we I'd year. the we're focused to for summarize questions, the get milestones the In quarter, following on
our families to and up ramping US marketing patients Oncology our we're within target network. Care First,
Second, Care close and of we marketing, broad-based to AVRT social on And are acquisition. direct-to-consumer campaigns, the finally, launch plan with for in media the key markets. planning to we Oncology Aristotle launch
partners, For a including campaign and marketing planning the and BXB targeting remainder partners, we are re-insureds. of the self-insured, year, channel
targeting strong adopter marketing employer trends, on planning we're will we're liquid and the campaigns. And to innovators long early with our The launch capitalize to term. of these third, the Second, to further company telehealth programs biopsy achievement and strategy milestones for pilot and advance with groups. employer national grow BXB our BXC multi-channel and
of Aristotle generating managing patient our use treatment, I And the on near revenue our we at long-term and happy chronic to online be that, journey from of that looking questions. just adjunctive As your biopsy and questions. what testing, lot take multi-cancer continue leveraging move through panel, forward, do a cancer testing, technology strategy, I'm to broaden liquid diseases. the operator, to intervention we COVID will a execute is, other term expanding includes; complete of into our we’d With telehealth will
with answering I before should begin think some it go to those of live. we
and a are the lack during US, particularly of sort cancer key in is the of how time still of think COVID. I through tests think this I of thrust marketed to coming understanding the
so lot have a of we investors. Canadian And
relatively I terms are in to a possibly as how I effectively you, marketed, them. new in US, FDA lot done under have products can, this. would we We to be able investors strongly of, of to launched, guide be guidance as familiar to become order think, in market the have with
faster. A The is that is individual familiar have as both is physician, cancer. with lot accessed by tests it's programs. they is, shorter, our be by rules relaxed. example, could of kind it's are think I not very by into the very got what prescribed and with questions of COVID This a your to COVID a also to yes, different. be series being push is, individual we've Cancer physician. accessed Cancer of your own about, Aristotle own you physician? can There that be answer were for so
COVID, the think about we've time before big to during However, I coming we about about think of at think to the individual moment. into this, the through physicians. you to when have talked And get we've pharma worked how it
real the we sales as quickly. of up back not They’re forces that. are it's There's will come not to through physician open going move very offices. It the still begin All reason a to in but idled. year, for very
it, and refer The physician to with actually one at realize this. getting groups. be testing, as have So amazing to in I be on terms Care support model large to not right who hire Why? to to us, slowly this who at them new oncology get access point, go have talking physician of reps, And offices, It's ability to and throw lot in it this. offices and has lead think not a with. come of also, with as is we're at available the time actually very model. you you Because to The from board groups we're and the the It's cost-effective involved physicians. physician to get Oncology that. of through sort a to then take actually you'll we've looked a wants is now. it, through
has into the result, get very Oncology, the a Care that, We've How actually get be able have can in particularly situation? current group order COVID You all employers with the it the we positive about to positive talked a do before employers. to actually with be thing the same with the board, deal exact deal to like results. program, have before, the on you entry dealt You plus we that often in also, to with. it's
we're programs just but of also US. will series of side beginning program like a drug importance And your of move Having actually at that the As to available into major not out a a it. is these Rexall. tests stores, in local the are Canadian out, into the falling of all place, underestimate whole border, don't on coup, it's and the beginning a drive
again, go to So, there. need
FDA is that The can no get to insurance. my these one, terms paid be That They questions to approved. five other including can thing and physician tests in for I be USPSTF to in a order not In insurance? to situation. all order of test that. it and they There paid is have through Why have just are about that have insurance, seven-year process. competitors, by for the ourselves go by our
in how in are educated that correct very run moving the needs you, marketplace. dealing and we're that. are through to as system the all works Therefore, reasons I Again, on States. the would the please United to why We There down guide clear it get they’re private we, the reasons. path
I think just looking the answer live we can process. That, in in And some with fact, before actual intent the the banks. final take piece that. have to listed is of to whether being working we confirm US and is questions in yes, US still
will appropriate an We that at point. do
so, can some And to I we live Rebecca, questions? hand over have Do it you?
